Philogen S.p.A.

PHIL

IT0005373789

Biotechnology & Medical Research

Market Closed - Borsa Italiana Other stock markets 11:44:59 2024-07-12 am EDT			5-day change	1st Jan Change
20.5 ^EUR	-0.97%		0.00%	+10.81%

Jul. 10	Transcript : Philogen S.p.A. - Special Call
Jun. 28	Stock markets in green galvanized by inflation data	AN

Philogen S.p.A. Enters Collaboration and License Agreement with Novartis

January 23, 2019 at 11:01 am EST

Philogen S.p.A. announced that they have entered into a collaboration and license agreement with Novartis to discover and develop a new class of immunomodulatory therapeutics.

Latest news about Philogen S.p.A.

Transcript : Philogen S.p.A. - Special Call	Jul. 10
Stock markets in green galvanized by inflation data	Jun. 28	AN
Markets bullish; MPS and Tenaris do well on Mib.	Jun. 28	AN
Futures bullish; inflation data expected	Jun. 28	AN
Stock exchanges in the red on eve of US PCE	Jun. 27	AN
Mib drops to 33,400; strength on Leonardo and Cucinelli	Jun. 27	AN
Mib down slightly; strength on Brunello Cucinelli	Jun. 27	AN
Futures in green; German hiring falls	Jun. 26	AN
Mib down; Saipem and Eni close higher	Jun. 25	AN
Mib advances; BPER Bank acts as locomotive	Jun. 17	AN
Futures up slightly on ECB day	Jun. 06	AN
Mib bullish ahead of ECB; STM and Nexi soar	Jun. 05	AN
Mib rises; ECB could push cyclical stocks up	Jun. 05	AN
Mib up at start, DiaSorin good on FDA news	Jun. 05	AN
Indices expected to rise before PMIs	Jun. 05	AN
Mib bearish; Brunello Cucinelli the best	Jun. 04	AN
Mib falls in 34,100 area dragged by banks	Jun. 04	AN
Philogen, Inc. and Sun Pharmaceutical Industries Limited Announces Results of the Phase III PIVOTAL Trial of Nidlegy in Melanoma	May. 31	CI
Mib pegs 34,300; banking segment well	May. 30	AN
Mib veers upward; ERG takes top spot	May. 30	AN
Sales in Milan; but Philogen is at annual peak	May. 29	AN
Futures down; Brent advances to USD84 area	May. 29	AN
Mib in the red; BPER and Intesa resist declines	May. 28	AN
Mib down but Iveco and Pirelli soar	May. 24	AN
Philogen, NFP and liquidity drop in first quarter	May. 07	AN

Philogen SpA is an Italy-based company, operating in the biotechnology sector. The Company develops products and technologies for the diagnosis and therapy of serious human diseases. It has three anti-cancer antibody derivatives, produced with an in-house industrial process, into Phase I/II clinical studies. The majority of its technologies and products are based on high-affinity human monoclonal antibody fragments. Philogen SpA developed a patented technology, Iterative Colony Filter Screening, for the isolation of monoclonal antibodies, which requires neither immunization nor phage display. The Company's subsidiaries are Philotec, Philomed and Philochem. Philogen SpA is headquartered in Siena, Italy.

Sector

Biotechnology & Medical Research

Calendar

2024-09-24 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Philogen S.p.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

20.5 EUR

Average target price

23.5 EUR

Spread / Average Target

+14.63%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PHILOGEN S.P.A.	+10.81%	901M
VERTEX PHARMACEUTICALS INCORPORATED	+20.12%	126B
REGENERON PHARMACEUTICALS, INC.	+25.25%	119B
ARGENX SE	+25.56%	27.95B
BIONTECH SE	-19.51%	20.5B
GENMAB A/S	-14.36%	17.12B
BEIGENE, LTD.	-15.63%	16.1B
WUXI APPTEC CO., LTD.	-46.67%	14.97B
NEUROCRINE BIOSCIENCES, INC.	+11.89%	14.84B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B

Bio Therapeutic Drugs

Philogen S.p.A.

Equities

PHIL

IT0005373789

Biotechnology & Medical Research

Philogen S.p.A. Enters Collaboration and License Agreement with Novartis

Latest news about Philogen S.p.A.

Chart Philogen S.p.A.

Company Profile

Income Statement Evolution

Ratings for Philogen S.p.A.

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Bio Therapeutic Drugs